SYRS Stock Overview
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines.
Syros Pharmaceuticals, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.41|
|52 Week High||US$43.30|
|52 Week Low||US$3.37|
|1 Month Change||-18.03%|
|3 Month Change||-49.61%|
|1 Year Change||-91.76%|
|3 Year Change||-92.85%|
|5 Year Change||-96.42%|
|Change since IPO||-98.12%|
Recent News & Updates
Syros Pharmaceuticals (NASDAQ:SYRS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, AnywayNov 08
Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) CEO Will Probably Find It Hard To See A Huge Raise This YearJun 02
Analysts Just Made A Substantial Upgrade To Their Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) ForecastsMay 11
Does Syros Pharmaceuticals (NASDAQ:SYRS) Have A Healthy Balance Sheet?May 07
Can You Imagine How Syros Pharmaceuticals' (NASDAQ:SYRS) Shareholders Feel About The 57% Share Price Increase?Mar 02
What Kind Of Investors Own Most Of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS)?Jan 26
Why Syros Pharmaceuticals' (NASDAQ:SYRS) CEO Pay MattersDec 08
|SYRS||US Biotechs||US Market|
Return vs Industry: SYRS underperformed the US Biotechs industry which returned -6.5% over the past year.
Return vs Market: SYRS underperformed the US Market which returned -17.6% over the past year.
|SYRS Average Weekly Movement||13.4%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: SYRS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: SYRS's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd.
Syros Pharmaceuticals, Inc. Fundamentals Summary
|SYRS fundamental statistics|
Is SYRS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SYRS income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-5.62|
|Net Profit Margin||-485.12%|
How did SYRS perform over the long term?See historical performance and comparison